McCoubrey Laura E, Thomaidou Stavriani, Elbadawi Moe, Gaisford Simon, Orlu Mine, Basit Abdul W
Department of Pharmaceutics, UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Pharmaceutics. 2021 Nov 25;13(12):2001. doi: 10.3390/pharmaceutics13122001.
Over 150 drugs are currently recognised as being susceptible to metabolism or bioaccumulation (together described as depletion) by gastrointestinal microorganisms; however, the true number is likely higher. Microbial drug depletion is often variable between and within individuals, depending on their unique composition of gut microbiota. Such variability can lead to significant differences in pharmacokinetics, which may be associated with dosing difficulties and lack of medication response. In this study, literature mining and unsupervised learning were used to curate a dataset of 455 drug-microbiota interactions. From this, 11 supervised learning models were developed that could predict drugs' susceptibility to depletion by gut microbiota. The best model, a tuned extremely randomised trees classifier, achieved performance metrics of AUROC: 75.1% ± 6.8; weighted recall: 79.2% ± 3.9; balanced accuracy: 69.0% ± 4.6; and weighted precision: 80.2% ± 3.7 when validated on 91 drugs. This machine learning model is the first of its kind and provides a rapid, reliable, and resource-friendly tool for researchers and industry professionals to screen drugs for susceptibility to depletion by gut microbiota. The recognition of drug-microbiome interactions can support successful drug development and promote better formulations and dosage regimens for patients.
目前有超过150种药物被认为易受胃肠道微生物代谢或生物累积(统称为消耗)的影响;然而,实际数量可能更多。微生物对药物的消耗在个体之间和个体内部通常存在差异,这取决于他们独特的肠道微生物群组成。这种变异性可能导致药代动力学的显著差异,这可能与给药困难和药物反应缺乏有关。在本研究中,通过文献挖掘和无监督学习整理了一个包含455种药物-微生物群相互作用的数据集。从中开发了11个监督学习模型,这些模型可以预测药物对肠道微生物群消耗的敏感性。最佳模型是一个经过调优的极端随机树分类器,在对91种药物进行验证时,其性能指标为:曲线下面积(AUROC):75.1%±6.8;加权召回率:79.2%±3.9;平衡准确率:69.0%±4.6;加权精确率:80.2%±3.7。这种机器学习模型尚属首次,为研究人员和行业专业人士提供了一种快速、可靠且资源友好的工具,用于筛选药物对肠道微生物群消耗的敏感性。对药物-微生物组相互作用的认识可以支持成功的药物开发,并为患者推广更好的制剂和给药方案。